Tianjin Zhongxin Pharmaceutical Group Corp Ltd

SHG:600329 China Drug Manufacturers - Specialty & Generic
Market Cap
$3.23 Billion
CN¥23.72 Billion CNY
Market Cap Rank
#4468 Global
#457 in China
Share Price
CN¥41.60
Change (1 day)
-0.57%
52-Week Range
CN¥29.42 - CN¥50.05
All Time High
CN¥54.12
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmologic… Read more

Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329) - Net Assets

Latest net assets as of September 2025: CN¥9.02 Billion CNY

Based on the latest financial reports, Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329) has net assets worth CN¥9.02 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥11.59 Billion) and total liabilities (CN¥2.56 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥9.02 Billion
% of Total Assets 77.89%
Annual Growth Rate 8.01%
5-Year Change 31.93%
10-Year Change 91.22%
Growth Volatility 12.0

Tianjin Zhongxin Pharmaceutical Group Corp Ltd - Net Assets Trend (1998–2024)

This chart illustrates how Tianjin Zhongxin Pharmaceutical Group Corp Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Tianjin Zhongxin Pharmaceutical Group Corp Ltd (1998–2024)

The table below shows the annual net assets of Tianjin Zhongxin Pharmaceutical Group Corp Ltd from 1998 to 2024.

Year Net Assets Change
2024-12-31 CN¥7.85 Billion +18.13%
2023-12-31 CN¥6.65 Billion +1.42%
2022-12-31 CN¥6.55 Billion +0.59%
2021-12-31 CN¥6.51 Billion +9.48%
2020-12-31 CN¥5.95 Billion +7.73%
2019-12-31 CN¥5.52 Billion +9.28%
2018-12-31 CN¥5.05 Billion +9.27%
2017-12-31 CN¥4.63 Billion +7.51%
2016-12-31 CN¥4.30 Billion +4.80%
2015-12-31 CN¥4.11 Billion +39.32%
2014-12-31 CN¥2.95 Billion +14.43%
2013-12-31 CN¥2.57 Billion +13.00%
2012-12-31 CN¥2.28 Billion +3.34%
2011-12-31 CN¥2.21 Billion +5.66%
2010-12-31 CN¥2.09 Billion +16.71%
2009-12-31 CN¥1.79 Billion +21.42%
2008-12-31 CN¥1.47 Billion +9.45%
2007-12-31 CN¥1.35 Billion -4.45%
2006-12-31 CN¥1.41 Billion -27.74%
2005-12-31 CN¥1.95 Billion +3.80%
2004-12-31 CN¥1.88 Billion +2.11%
2003-12-31 CN¥1.84 Billion +8.85%
2002-12-31 CN¥1.69 Billion +9.61%
2001-12-31 CN¥1.54 Billion +33.86%
2000-12-31 CN¥1.15 Billion +0.77%
1999-12-31 CN¥1.14 Billion +7.89%
1998-12-31 CN¥1.06 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Tianjin Zhongxin Pharmaceutical Group Corp Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 7568.3% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥5.64 Billion 71.84%
Common Stock CN¥770.09 Million 9.82%
Other Comprehensive Income CN¥572.05 Million 7.29%
Other Components CN¥866.42 Million 11.05%
Total Equity CN¥7.84 Billion 100.00%

Tianjin Zhongxin Pharmaceutical Group Corp Ltd Competitors by Market Cap

The table below lists competitors of Tianjin Zhongxin Pharmaceutical Group Corp Ltd ranked by their market capitalization.

Company Market Cap
Telix Pharmaceuticals Limited
PINK:TLPPF
 		$2.42 Billion
Alior Bank S.A.
WAR:ALR
 		$2.42 Billion
Hercules Capital Inc
NYSE:HTGC
 		$2.42 Billion
Chunghwa Precision Test Tech Co Ltd
TWO:6510
 		$2.42 Billion
TBC Bank Group PLC
PINK:TBCCF
 		$2.42 Billion
Crane NXT Co
NYSE:CXT
 		$2.42 Billion
K&S AG
OTCQX:KPLUF
 		$2.42 Billion
APT Medical Inc
SHG:688617
 		$2.42 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Tianjin Zhongxin Pharmaceutical Group Corp Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 6,600,690,542 to 7,843,592,378, a change of 1,242,901,836 (18.8%).
  • Net income of 2,229,334,241 contributed positively to equity growth.
  • Dividend payments of 1,010,588,611 reduced retained earnings.
  • Share repurchases of 282,342 reduced equity.
  • Other comprehensive income decreased equity by 15,665,335.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥2.23 Billion +28.42%
Dividends Paid CN¥1.01 Billion -12.88%
Share Repurchases CN¥282.34K -0.0%
Other Comprehensive Income CN¥-15.67 Million -0.2%
Other Changes CN¥40.10 Million +0.51%
Total Change CN¥- 18.83%

Book Value vs Market Value Analysis

This analysis compares Tianjin Zhongxin Pharmaceutical Group Corp Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 4.09x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 28.82x to 4.09x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2000-12-31 CN¥1.44 CN¥41.60 x
2001-12-31 CN¥1.97 CN¥41.60 x
2002-12-31 CN¥2.05 CN¥41.60 x
2003-12-31 CN¥2.17 CN¥41.60 x
2004-12-31 CN¥2.18 CN¥41.60 x
2005-12-31 CN¥2.22 CN¥41.60 x
2006-12-31 CN¥1.63 CN¥41.60 x
2007-12-31 CN¥1.51 CN¥41.60 x
2008-12-31 CN¥1.68 CN¥41.60 x
2009-12-31 CN¥2.06 CN¥41.60 x
2010-12-31 CN¥2.45 CN¥41.60 x
2011-12-31 CN¥2.51 CN¥41.60 x
2012-12-31 CN¥2.91 CN¥41.60 x
2013-12-31 CN¥3.30 CN¥41.60 x
2014-12-31 CN¥3.71 CN¥41.60 x
2015-12-31 CN¥5.21 CN¥41.60 x
2016-12-31 CN¥5.37 CN¥41.60 x
2017-12-31 CN¥5.83 CN¥41.60 x
2018-12-31 CN¥6.40 CN¥41.60 x
2019-12-31 CN¥7.01 CN¥41.60 x
2020-12-31 CN¥7.55 CN¥41.60 x
2021-12-31 CN¥8.28 CN¥41.60 x
2022-12-31 CN¥8.40 CN¥41.60 x
2023-12-31 CN¥8.56 CN¥41.60 x
2024-12-31 CN¥10.17 CN¥41.60 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Tianjin Zhongxin Pharmaceutical Group Corp Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 28.42%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 30.51%
  • • Asset Turnover: 0.68x
  • • Equity Multiplier: 1.37x
  • Recent ROE (28.42%) is above the historical average (9.53%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2000 8.14% 10.51% 0.33x 2.38x CN¥-19.82 Million
2001 4.37% 4.16% 0.56x 1.88x CN¥-81.67 Million
2002 5.65% 4.63% 0.61x 2.00x CN¥-65.56 Million
2003 5.42% 4.19% 0.54x 2.38x CN¥-73.04 Million
2004 3.99% 3.04% 0.54x 2.44x CN¥-96.38 Million
2005 4.95% 3.23% 0.62x 2.49x CN¥-82.36 Million
2006 -32.19% -17.86% 0.62x 2.92x CN¥-506.64 Million
2007 -6.30% -3.10% 0.65x 3.13x CN¥-180.92 Million
2008 14.25% 7.45% 0.69x 2.79x CN¥52.57 Million
2009 16.97% 8.95% 0.79x 2.41x CN¥105.85 Million
2010 16.30% 8.44% 0.91x 2.13x CN¥113.31 Million
2011 13.15% 5.64% 1.06x 2.20x CN¥59.39 Million
2012 20.65% 8.60% 1.16x 2.07x CN¥227.61 Million
2013 14.55% 5.85% 1.14x 2.18x CN¥110.06 Million
2014 12.95% 5.05% 1.30x 1.97x CN¥81.42 Million
2015 11.51% 6.38% 1.17x 1.55x CN¥59.27 Million
2016 10.23% 6.79% 0.98x 1.54x CN¥9.63 Million
2017 10.63% 8.37% 0.86x 1.48x CN¥28.40 Million
2018 11.40% 8.83% 0.89x 1.44x CN¥68.98 Million
2019 11.61% 8.94% 0.89x 1.46x CN¥86.75 Million
2020 11.39% 10.02% 0.80x 1.43x CN¥80.86 Million
2021 12.08% 11.13% 0.76x 1.42x CN¥132.70 Million
2022 13.21% 10.45% 0.81x 1.56x CN¥209.65 Million
2023 14.95% 12.00% 0.80x 1.55x CN¥326.64 Million
2024 28.42% 30.51% 0.68x 1.37x CN¥1.44 Billion

Industry Comparison

This section compares Tianjin Zhongxin Pharmaceutical Group Corp Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,123,990,643
  • Average return on equity (ROE) among peers: -0.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329) CN¥9.02 Billion 8.14% 0.28x $2.42 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million